5-HT1A/1B receptor antagonist, with roughly equal affinity for each subtype. A partial agonist at mouse and human β3-adrenoceptors.
S-enantiomer also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 248.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.03 mL||20.14 mL||40.27 mL|
|5 mM||0.81 mL||4.03 mL||8.05 mL|
|10 mM||0.4 mL||2.01 mL||4.03 mL|
|50 mM||0.08 mL||0.4 mL||0.81 mL|
References are publications that support the biological activity of the product.
Blin et al (1993) Structural and conformational features determining selective signal transduction in the β3-adrenergic receptor. Mol.Pharmacol. 44 1094 PMID: 7903415
Clifford et al (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br.J.Pharmacol. 124 206 PMID: 9630361
Corradetti et al (1998) Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br.J.Pharmacol. 123 449 PMID: 9504386
Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157 PMID: 7938165
Merck Index 12 7597
If you know of a relevant reference for Pindolol, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Pindolol, Pindolol supplier, 5-HT1A/1B, antagonists, β3-adrenoceptor, β3-adrenergic, b3-adrenoceptor, b3-adrenergic, partial, agonists, Serotonin, 5-HT1A, Receptors, 5-HT1B, Adrenergic, Beta-3, 0994, Tocris Bioscience
5 Citations for Pindolol
Citations are publications that use Tocris products. Selected citations for Pindolol include:
Marinelli et al (2004) Serotonergic and nonserotonergic dorsal raphe neurons are pharmacologically and electrophysiologically heterogeneous. J Neurophysiol 92 3532 PMID: 15254076
Luo (2017) β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro. Scientific Reports 7 39905 PMID: 28051147
Littmann et al (2015) Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands. Front Microbiol 355 183 PMID: 26306764
Zaytseva et al (2013) Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion. Sens Actuators B Chem 188 PMID: 24319319
Kleinbongard et al (2011) Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108 344 PMID: 21183739
Do you know of a great paper that uses Pindolol from Tocris? Please let us know.
Reviews for Pindolol
There are currently no reviews for this product. Be the first to review Pindolol and earn rewards!
Have you used Pindolol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.